Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer

被引：1
作者：
Bouhniz, Om Elez [1 ,2 ]
Kenani, Abderraouf [1 ]
机构：
[1] Univ Monastir, Fac Med Monastir, Res Lab Environm Inflammat Signaling & Pathol LR18, Monastir, Tunisia
[2] Univ Monastir, Fac Med Monastir, Res Lab Environm Inflammat Signaling & Pathol LR18, Monastir 5019, Tunisia
来源：
JOURNAL OF CHEMOTHERAPY | 2025年 / 37卷 / 02期
关键词：
Genetic polymorphisms; genes; neoadjuvant chemotherapy; breast cancer; therapy resistance; personalized medicine; PATHOLOGICAL RESPONSE; DRUG-RESISTANCE; ANTICANCER DRUG; IN-VITRO; P53; ASSOCIATION; EXPRESSION; CYTOCHROME-P450; THERAPY; ALLELE;
D O I：
10.1080/1120009X.2024.2330241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chemoresistance leads to treatment failure, which can arise through different mechanisms including patients' characteristics. Searching for genetic profiles as a predictor for drug response and toxicity has been extensively studied in pharmacogenomics, thus contributing to personalized medicine and providing alternative treatments. Numerous studies have demonstrated significant evidence of association between genetic polymorphisms and response to neoadjuvant chemotherapy (NAC) in breast cancer. In this review, we explored the potential impact of genetic polymorphisms in NAC primary resistance through selecting a specific clinical profile. The genetic variability within pharmacokinetics, pharmacodynamics, DNA synthesis and repair, and oncogenic signaling pathways genes could be predictive or prognostic markers for NAC resistance. The clinical implication of these results can help provide individualized treatment plans in the early stages of breast cancer treatment. Further studies are needed to determine the genetic hosts of primary chemoresistance mechanisms in order to further emphasize the implementation of genotypic approaches in personalized medicine.
引用
收藏
页码：97 / 111
页数：15
相关论文
共 84 条
[1]   A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC [J].
Adorni, Maria Pia ;
Galetti, Maricla ;
La Monica, Silvia ;
Incerti, Matteo ;
Ruffoni, Alessandro ;
Elviri, Lisa ;
Zanotti, Ilaria ;
Papotti, Bianca ;
Cavallo, Delia ;
Alfieri, Roberta ;
Petronini, Pier Giorgio ;
Bernini, Franco .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
[2]  
AliOsman F, 1997, J BIOL CHEM, V272, P10004
[3]   New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer [J].
An, Junsha ;
Peng, Cheng ;
Tang, Hailin ;
Liu, Xiuxiu ;
Peng, Fu .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (17)
[4]   Treatment of HER2-positive breast cancer: current status and future perspectives [J].
Arteaga, Carlos L. ;
Sliwkowski, Mark X. ;
Osborne, C. Kent ;
Perez, Edith A. ;
Puglisi, Fabio ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) :16-32
[5]   Advances and challenges in targeting FGFR signalling in cancer [J].
Babina, Irina S. ;
Turner, Nicholas C. .
NATURE REVIEWS CANCER, 2017, 17 (05) :318-332
[6]   The effect of folate-related SNPs on clinicopathological features, response to neoadjuvant treatment and survival in pre- and postmenopausal breast cancer patients [J].
Babyshkina, Nataliya ;
Malinovskaya, Elena ;
Nazarenko, Mariya ;
Koval, Mariya ;
Gervas, Polina ;
Potapova, Olga ;
Slonimskaya, Elena ;
Cherdyntseva, Nadejda .
GENE, 2013, 518 (02) :397-404
[7]   Stable overexpression of DNA fragmentation factor in T-47D cells: sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide [J].
Bagheri, Fatemeh ;
Safarian, Shahrokh ;
Eslaminejad, Mohamadreza Baghaban ;
Sheibani, Nader .
MOLECULAR BIOLOGY REPORTS, 2014, 41 (11) :7387-7394
[8]  
Bartsch Helmut, 2007, V174, P19
[9]   Potential Role of Circulating miRNAs for Breast Cancer Management in the Neoadjuvant Setting: A Road to Pave [J].
Benvenuti, Chiara ;
Tiberio, Paola ;
Gaudio, Mariangela ;
Jacobs, Flavia ;
Saltalamacchia, Giuseppe ;
Pindilli, Sebastiano ;
Zambelli, Alberto ;
Santoro, Armando ;
De Sanctis, Rita .
CANCERS, 2023, 15 (05)
[10]   COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].
BERGH, J ;
NORBERG, T ;
SJOGREN, S ;
LINDGREN, A ;
HOLMBERG, L .
NATURE MEDICINE, 1995, 1 (10) :1029-1034
123456789